ClinicalTrials.gg
RecruitingNCT06787560Updated Jan 22, 2025

CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases

An Early Phase 1 interventional study of CD7 CAR-T cells injection and Allo-HSCT in Bone Marrow Failure Syndrome, sponsored by Zhejiang University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Zhejiang University · Early Phase 1, Interventional, and Treatment

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Study summary

A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases

Read the detailed description

This is a single-arm, open-label clinical trial to evaluate the safety and efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases. It is planned to enroll 12-20 participants in this trial.

02

Conditions studied

  • Bone Marrow Failure Syndrome

Keywords

  • CAR-T
  • Allo-HSCT
  • Immuno Deficiency Disorders
03

In context

Bone Marrow Failure Disorders

91 studies on the registry are indexed under Bone Marrow Failure Disorders; 29 are open to participants now.

This study's planned enrollment of 20 is below the median of 26 across 69 interventional studies indexed under Bone Marrow Failure Disorders.

Browse Bone Marrow Failure Disorders studies →

Lead sponsor

Zhejiang University is the lead sponsor of 356 studies on the registry; 166 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Non-malignant blood and immune system diseases include: hereditary bone marrow failure, congenital immune deficiency, hemoglobinopathy and other non-malignant blood and immune system diseases,

      1. Confirmed hereditary bone marrow failure syndrome. Including: Fanconi anemia, congenital pure red cell aplastic anemia, congenital dyskeratosis, Scheux-Day syndrome, congenital neutropenia, various bone marrow failure related congenital thrombocytopenia and other unclassified congenital bone marrow exhaustion diseases;
      2. It meets the criteria of clinical manifestation, immune function and gene diagnosis of immune deficiency disease;
      3. Diagnosed with hemoglobinopathy and dependent on blood transfusions; serum ferritin levels are \< 3000 μg/L, with cardiac and hepatic iron content indicating moderate or lower iron overload; documentation of iron chelation therapy (including prescriptions or invoices) for at least three months prior to screening is available; no hydroxyurea, ruxolitinib, decitabine, or cytarabine has been administered in the three months preceding enrollment. The spleen size must not extend beyond the umbilical horizontal line or the midline of the abdomen. hematopoietic stem cell transplantation (allo-HSCT) is indicated, and suitable donors for related allo-HSCT are available.
    1. Serum total ≤1.5 times the value, serum (ALT) and Aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal value range;
    1. Echocardiography showed (LVEF) >50%;
    1. Pulse oxygen saturation ≥92% (non-oxygen state);
    1. The estimated survival is more than 3 months;
    1. score 0-1;
    1. Abdominal B-ultrasonography and other examinations were performed to evaluate spleen size. Splenectomy should be evaluated before transplantation for patients with giant spleen;
    1. Women and men who are fertile must consent to the use of appropriate before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);
    1. Subjects who are willing to participate in the study are able to understand and have the ability to sign .

Exclusion criteria

Exclusion Criteria:

    1. People with a history of epilepsy or other central nervous system disorders;
    1. Epstein-Barr virus (EBV) DNA positive;
    1. People with a history of prolonged or serious heart disease;
    1. People with active or C virus;
    1. Tuberculosis, AIDS and other major infectious diseases;
    1. Sepsis, pulmonary infection, intestinal infection and other major organ infection and poor control, and/or hypersensitive C-reactive protein, procalcitonin significantly elevated;
    1. People who have previously received other clinical studies and gene therapy;
    1. Any situation that the investigator believes may increase the risk to the subject or interfere with the test results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CD7 CAR-T cells( CD7 chimeric antigen receptor T cells)

    Patients or donors undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with CTX、Flu、VP-16 before CAR-T cells infusion. CAR-T cells could be transfused after 48 hours of preconditioning.

    Biological: CD7 CAR-T cells injection · Procedure: Allo-HSCT

Interventions

  • Each subject receive CD7 CAR T-cells by intravenous infusion

  • ProcedureAllo-HSCT

    allogeneic hematopoietic stem cell transplantation

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events

    Time frame: Up to 2 years after Treatment

  2. Transplant related mortality rate

    The proportion of patients who died after transplantation to the total number of transplant patients during the same period

    Time frame: Up to 100 days after Treatment

Secondary outcomes

  1. Allogeneic hematopoietic stem cell transplant implantation rate

    The proportion of the number of patients who achieved hematopoietic reconstitution to the total number of allogeneic hematopoietic stem cell transplantation patients in the same period.

    Time frame: Up to 100 days after Treatment

  2. Time to neutrophil and platelet engraftment

    The time for neutrophils and platelets to reach the implantation criteria after stem cell reinfusion

    Time frame: Up to 30 days after Treatment

  3. Disease-feesurvival,DFS

    The proportion of disease-free patients who survived to the total number of patients who transplanted allogeneic hematopoietic stem cells during the same period.

    Time frame: Up to 2 years after Treatment

  4. Overall survival, OS

    After transplantation until death from any cause.

    Time frame: Up to 2 years after Treatment

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06787560
Collaborators
Yake Biotechnology Ltd.
Responsible party
He Huang (Principal Investigator, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Jan 22, 2025
Start date
Jan 31, 2025 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Jan 22, 2025

Study contacts

He Huang, MD
Contact
hehuangyu@126.com
0571-87233772
Yongxian Hu, MD
Contact
huyongxian2000@aliyun.com
0571-87233772
He Huang, MD
principal investigator · Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD7 CAR T-cells

Start the discussion